Fig. 6

5hmC biomarkers have higher prediction performance than traditional markers in detecting metastasis and recurrence. A ROC curve analyzing traditional tumor markers in the validation cohort of ESCC patients with metastasis. B-C ROC curves for 14 5hmC biomarkers in the validation cohort of ESCC patients with metastasis. D ROC curve examining traditional tumor markers in the validation cohort of ESCC patients with recurrence. E–F ROC curves for 14 5hmC biomarkers in the validation cohort of ESCC patients with recurrence, plotting the true positive rate (sensitivity) against the false positive rate (1-specificity)